GlassScriptPhysician profile
John R Carradine
NPI 1841224565
$10,873.42
in general payments reported to CMS, 2019-2025
31 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 93% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,900 · 2020: $435 · 2021: $1,449 · 2022: $1,512 · 2023: $1,160 · 2024: $644 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,359 · Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,359.32 |
| Food and Beverage | $2,218.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,300.05 | 2019-2025 | Ortholoc 2 Lapifuse, Asnis, Fixos |
| Anika Therapeutics, INC. | $1,173.80 | 2021 | |
| Vilex LLC | $1,093.67 | 2025 | Hintermann |
| Medline Industries LP | $911.83 | 2021-2022 | |
| International Life Sciences | $674.70 | 2023 | |
| Alon Medical Technology | $630.84 | 2025 | |
| Arthrex, INC. | $484.90 | 2025 | |
| Horizon Therapeutics Plc | $401.30 | 2019-2022 | |
| Sanara Medtech INC. | $347.20 | 2024-2025 | Celleraterx, Celleraterx |
| Wright Medical Technology, INC. | $311.30 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $261.14 | 2022-2025 | Nuzyra |
| Organogenesis INC. | $200.23 | 2022-2024 | Puraply |
| Amgen INC. | $185.83 | 2019-2025 | Prolia, Evenity, Krystexxa |
| Bone Support INC. | $142.57 | 2024 | Ceramentbone Void Filler, Cerament G |
| Trilliant Surgical LLC. | $140.43 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Solutions INC | $109.03 | 2019 | |
| Biopoly LLC | $75.74 | 2023 | |
| Pacira Therapeutics, INC. | $71.29 | 2019-2021 | |
| Smith+Nephew, INC. | $60.40 | 2019-2023 | Stravix, Stravix Pl, Grafix Pl |
| Nevro Corp. | $45.10 | 2019-2020 | |
| Convatec INC. | $41.15 | 2023 | |
| Radius Health, INC. | $36.62 | 2019-2025 | |
| Biocomposites INC | $31.44 | 2025 | Stimulan |
| Baxter Healthcare | $30.05 | 2024 | |
| Zyla Life Sciences, INC. | $24.13 | 2019 | |
| Davol INC. | $22.57 | 2023 | Arista Ah Flexitip |
| Endo Pharmaceuticals INC. | $14.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.90 | 2023 | |
| Kerecis Limited | $13.75 | 2021 | |
| Abbvie INC. | $12.81 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carradine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.